COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

A Phase II Trial of OnapriStone in CoMbInation with FuLvestrant for Patients with ER-positive, and HER2-negative Metastatic Breast Cancer after Progression on Endocrine Therapy and CDK 4/6 inhibitors

Protocol No
WON-UW20037-SMILE-ONAPRISTONE
Principal Investigator
Sailaja Kamaraju
Phase
II
Summary
We want to find out if a drug called onapristone, in combination with fulvestrant, can stop or slow metastatic breast cancer. We also want to find out if onapristone, in combination with fulvestrant, is safe to use to treat metastatic breast cancer. Onapristone is an investigational drug. This means that the US Food and Drug Administration (FDA) has not approved onapristone for the treatment of metastatic breast cancer, and onapristone can only be given in a research study.
Description
This study will find out if a drug called onapristone, in combination with fulvestrant, can stop or slow metastatic breast cancer.
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Sub Category